A recent study reported that PD-1 antibody blockade increases the immune response of NK cells both in an MHC-Ineg and MHC-Ipos tumor setting (Hsu et al., 2018), supporting the notion that NK cells participate in the clinical benefit of PD-1/PD-L1 antibody therapy. This evidence concerns the gene PDCD1 and neoplasm.